Tag: EO2463
-
EO2463 Wins FDA Fast Track for Follicular Lymphoma: A New Immunotherapy Hope
FDA Grants Fast Track Designation to EO2463 for Follicular Lymphoma The U.S. FDA has granted Fast Track designation to EO2463, a novel immunotherapy from Enterome, aimed at treating follicular lymphoma (FL), a typically slow-progressing yet incurable form of indolent non-Hodgkin lymphoma. The designation follows encouraging interim results from the ongoing phase 2 SIDNEY trial (NCT04669171)…
-
FDA Fast Track for EO2463 Immunotherapy Brings Hope for Follicular Lymphoma Patients
Overview: A New Immunotherapy Candidate in Follicular Lymphoma The FDA has awarded Fast Track designation to EO2463, Enterome’s novel immunotherapy designed for follicular lymphoma (FL), an indolent but often relapsing form of non-Hodgkin lymphoma. Grounded in promising interim data from the SIDNEY phase 2 trial, EO2463 represents a strategic effort to harness the immune system…
-
FDA Fast Track for EO2463 Immunotherapy Could Accelerate Follicular Lymphoma Treatment
FDA Grants Fast Track Designation to EO2463 for Follicular Lymphoma The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to EO2463, a novel immunotherapy from Enterome, aimed at treating follicular lymphoma (FL), a common indolent form of non-Hodgkin lymphoma (NHL). This decision is based on encouraging interim results from the ongoing phase…